Abstract:Human papillomavirus (HPV) causes ∼700.000 new cancer cases annually, with HPV16 being the most important HPV type. The viral oncoproteins E6 and E7 drive the malignant transformation of persistent HPV infections. Thus, epitopes derived from these proteins are optimal candidates for therapeutic vaccination against HPV-mediated tumors/precursor lesions. However, the epitopes presented are specific to the individual human leukocyte antigen (HLA) molecules. Fortunately, the number of epitopes required for broad population coverage can be reduced by exploitation of HLA supertypes. A combination of epitopes binding to six major HLA supertypes (A1, A2, A3/A11, A24, B7 and B62) allows >99% world population coverage. To identify peptides against which successful immune responses have been induced naturally, interferon-γ ELISpot assays and flow cytometry-based intracellular cytokine staining (ICS) were performed with peripheral blood mononuclear cells (PBMCs) of healthy female donors above 40 years of age. In the ELISpots, 87 donors were analyzed with at least ten donors for each HLA supertype and an overall response rate of 76%. So far, we have identified 40 peptides inducing specific CD8 T cell activation in the ICS with at least 2 reactive peptides per HLA supertype. The most promising epitopes were selected for functional characterization in a newly established highly sensitive image-based cytotoxicity assay. This assay applies time-course analysis to enable the detection of specific killing executed by rare T cell populations derived from PBMCs. Up to now, several HLA-A2, -A24-and -A11-binding epitopes were validated to mediate epitope-specific killing by T cells in at least one donor. The analysis of additional donors, epitopes and HLA-supertypes is ongoing. In parallel to the immunogenicity analysis of healthy donors, the presentation of epitopes on HPV16-transformed cancer cell lines of different HLA backgrounds and malignancies was analyzed by targeted liquid chromatography-mass spectrometry (LC-MS). For this, LC-MS characteristics of target peptides (e.g. exact retention time, fragmentation pattern, and preferred precursor charge state) were acquired in order to determine optimal parameters for each peptide, resulting in ultra-high detection sensitivity. Peptide eluates from immunoprecipitated HLA-complexes of 22 cell lines were analyzed, leading to the identification of more than 20 peptides and at least one peptide per investigated HLA supertype. Interestingly, there is only a partial overlap between the data obtained by immunogenicity analysis and those acquired by targeted LC-MS. This might indicate a shift in the presented epitope repertoire in the course of disease progression and highlights the importance of inducing an immune response tailored to the correct target epitopes. In conclusion, the presented study provides a validated map of the HPV-16 E6-and E7-derived epitope repertoire, which will serve as a rational basis for the development of therapeutic HPV vaccines as well as other epitope-centric HPV16 immunotherapies. Citation Format: Kathrin Wellach, Maria Bonsack, Jonas D Förster, Nika Vuckovic, Jonas P Becker, Angelika B Riemer. A pan-HLA HPV16 T cell epitope repertoire – validated by immunopeptidomics and immunogenicity analysis – for therapeutic vaccine design [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B055.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Tlr Agonists Activate Hpv11 E7-Pulsed Dcs to Promote A Specific T Cell Response in A Murine Model

Toll Like Receptor Agonists Augment HPV 11 E7-specific T Cell Responses by Modulating Monocyte-Derived Dendritic Cells

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Dual T cell receptor/chimeric antigen receptor engineered NK‐92 cells targeting the HPV16 E6 oncoprotein and the tumor‐associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells

Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods

Abstract B055: A pan-HLA HPV16 T cell epitope repertoire – validated by immunopeptidomics and immunogenicity analysis – for therapeutic vaccine design

Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice

S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes

Abstract 26: An HLA-class II restricted HPV18 E7 specific TCR cloned from a long-term surviving cervical cancer patient

Glycan-costumed virus-like particles promote type 1 anti-tumor immunity

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice

Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates

Abstract 481: Proteomimetic polymers limit tumor growth in multiple models via potent antigen-specific T cell activation

Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer

Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine

Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens